Alnylam Delivers 52% Product Revenue Growth in Q3, but Analysts Flag Slowing Amvuttra Momentum and Pipeline Delays
TTR franchise powers Alnylam’s Q3 results. Analysts cite decelerating Amvuttra growth and minor catalyst delays; Stifel cuts to Hold.
TTR franchise powers Alnylam’s Q3 results. Analysts cite decelerating Amvuttra growth and minor catalyst delays; Stifel cuts to Hold.
Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
Alnylam cuts 2026 Amvuttra sales guidance to $4.2B–$4.5B due to slower growth in second-line ATTR-CM demand.
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.
Alnylam Pharmaceuticals partners with AI startup Inceptive in a deal worth up to $2 billion to accelerate discovery of next-generation RNAi therapeutics using powerful AI models.